1 |
Balasubramanian S, Verner, Buggy JJ (2009). Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett, 280, 211-21.
DOI
ScienceOn
|
2 |
Blaheta RA, Cinatl J, Jr. (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev, 22, 492-511.
DOI
ScienceOn
|
3 |
Butler LM, Zhou X, Xu WS, et al (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Porc Natl Acad Sci USA, 99, 11700-5.
DOI
ScienceOn
|
4 |
Chen MY, Liao WS, Lu Z, et al (2011). Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer, 117, 4424-38.
DOI
ScienceOn
|
5 |
Cinatl J, Jr., Cinatl J, Driever PH, et al (1997). Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticaner Drugs, 8, 958-63.
DOI
ScienceOn
|
6 |
Fritsche P, Seidler B, Schuler S, et al (2009). HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut, 58, 1399-409.
DOI
ScienceOn
|
7 |
Hejna M, Pruckmayer M, Raderer M (1998). The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer, 34, 977-86.
DOI
ScienceOn
|
8 |
Iwahashi S, Ishibashi H, Utsunomiya T, et al (2011). Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas and cholangiocarcinoma cell lines. J Med Invest, 58, 106-9.
DOI
|
9 |
Kelly WK, Marks PA (2005). Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol, 2, 150-7.
DOI
ScienceOn
|
10 |
Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51, 7-9.
DOI
|
11 |
Kumagai T, Wakimoto N, Yin D, et al (2007). Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer, 121, 656-65.
DOI
ScienceOn
|
12 |
Lee MA, Woo IS, Kang JH, et al (2004). Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol, 130, 346-50.
DOI
|
13 |
Limpaiboon T (2012). Epigenetic aberrat ions in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pac J Cancer Prev, 13, 41-5.
DOI
ScienceOn
|
14 |
Lin RJ, Nagy L, Inoue S, et al (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391, 811-4.
DOI
ScienceOn
|
15 |
Marks PA, Dokmanovic M (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investing Drug, 14, 1497-511.
DOI
ScienceOn
|
16 |
Martin R, Jarnagin W (2003). Intrahepatic cholangiocarcinoma. Current management. Minerva Chir, 58, 469-78.
|
17 |
Morine Y, Shimada M, Iwahashi S, et al (2012). Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery, 151, 412-9.
DOI
ScienceOn
|
18 |
Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol, 3, 33-42.
DOI
ScienceOn
|
19 |
Mutze K, Langer R, Becker K, et al (2010). Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol, 17, 3336-43.
DOI
|
20 |
Pan LN, Lu J, Huang B (2007). HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol, 4, 337-43.
|
21 |
Patra SK, Patra A, Dahiya R (2001). Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun, 287, 705-13.
DOI
ScienceOn
|
22 |
Patt YZ, Hassan MM, Lozano RD, et al (2001). Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res, 7, 3375-80.
|
23 |
Rikiishi H (2011). Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol, 2011, 830260.
|
24 |
Shao Y, Gao Z, Marks PA, et al (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Porc Natl Acad Sci USA, 101, 18030-5.
DOI
ScienceOn
|
25 |
Sharma S, Kelly TK, Jones PA (2010). Epigenetics in cancer. Carcinogenesis, 31, 27-36.
DOI
ScienceOn
|
26 |
Shukla V, Vaissiere T, Herceg Z (2008). Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res, 637, 1-15.
DOI
ScienceOn
|
27 |
Sia D, Tovar V, Moeini A, et al (2013). Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene, doi: 10.1038/onc.2012.617.
DOI
ScienceOn
|
28 |
Stiborova M, Eckschlager T, Poljakova J, et al (2012). The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem, 19, 4218-38.
DOI
|
29 |
Venkataramani V, Rossner C, Iffland L, et al (2010). Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem, 285, 10678-89.
DOI
|
30 |
Thongprasert S (2005). The role of chemotherapy in cholangiocarcinoma. Ann Oncol, 16, 93-6.
|
31 |
Vichai V, Kirtikara K (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1, 1112-6.
DOI
ScienceOn
|
32 |
Vigushin DM, Coombes RC (2002). Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13, 1-13.
DOI
ScienceOn
|
33 |
Weichert W, Roske A, Gekeler V, et al (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer, 98, 604-10.
DOI
ScienceOn
|
34 |
Xia Q, Sung J, Chowdhury W, et al (2006). Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res, 66, 7237-44.
DOI
ScienceOn
|
35 |
Yamaguchi J, Sasaki M, Sato Y, et al (2010). Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci, 101, 355-62.
DOI
ScienceOn
|
36 |
Zabron A, Edwards RJ, Khan SA (2013). The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech, 6, 281-92.
DOI
ScienceOn
|